Prognotic impact of serum follistatin in patients with hepatocellular carcinoma. Issue 8 (22nd July 2013)

• Record Type: Journal Article
• Authors: Tomoda, Takeshi; Nouso, Kazuhiro; Miyahara, Koji; Kobayashi, Sayo; Kinugasa, Hideaki; Toyosawa, Junki; Hagihara, Hiroaki; Kuwaki, Kenji; Onishi, Hideki; Nakamura, Shinichiro; Ikeda, Fusao; Miyake, Yasuhiro; Shiraha, Hidenori; Takaki, Akinobu; Yamamoto, Kazuhide
• Is Part Of: Journal of gastroenterology and hepatology. Volume 28:Issue 8(2013:Aug.)
• Page Start: 1391
• Page End: 1396
• Publication Date: 2013-07-22
• Subjects: Gastroenterology -- Periodicals; Digestive organs -- Diseases -- Periodicals; Liver -- Diseases -- Periodicals; Gastroenterology -- Periodicals; Liver Diseases -- Periodicals; 616.33
• DOI: 10.1111/jgh.12167
• Languages: English
• ISSNs: 0815-9319

Abstract

<abstract abstract-type="main"> <title>Abstract</title> <sec id="jgh12167-sec-0001" sec-type="section"> <title>Background and Aim</title> <p>Follistatin (FST) is a glycoprotein expressed in most organs, which interacts with activins or other members of the transforming growth factor beta family. Recently, several reports have shown that FST regulates a variety of processes during tumor progression. Here, serum FST in patients with liver diseases was measured, and its clinical utility as a biomarker was assessed.</p> </sec> <sec id="jgh12167-sec-0002" sec-type="section"> <title>Methods</title> <p>Serum was collected from 162 patients (91 hepatocellular carcinoma [HCC], 43 liver cirrhosis, and 28 chronic hepatitis) as well as from 16 healthy volunteers. FST was quantified by enzyme‐linked immunosorbent assays, and levels were compared with clinical parameters including survival of the HCC patients.</p> </sec> <sec id="jgh12167-sec-0003" sec-type="section"> <title>Results</title> <p>Median serum FST levels in HCC, liver cirrhosis, chronic hepatitis, and healthy volunteers were 1168, 1606, 1324, and 1661 pg/mL, respectively, not significantly different. In HCC patients, higher serum FST was associated with greater age, hepatitis C virus antibody‐negativity, large tumor size, g‐glutamyl transpeptidase, des‐gamma carboxyprothrombin and presence of portal vein tumor thrombus. Survival of HCC patients with high FST levels was significantly shorter than for those with low levels (<italic>P</italic> = 0.004). Multivariate analysis revealed that in addition to large tumor size and presence of portal vein thrombus, high FST levels were independently correlated with poor prognosis (hazard ratio = 2.41, 95% confidence interval = 1.16–5.00, <italic>P</italic> = 0.02).</p> </sec> <sec id="jgh12167-sec-0004" sec-type="section"> <title>Conclusions</title> <p>Serum FST levels are significantly associated with HCC prognosis and could represent a predictive biomarker in this disease.</p> </sec> </abstract>